Infliximab: new indication. Severe Crohn's disease in children: many unknowns.
The evidence from the only available trial of infliximab in children with severe Crohn's disease who have no other treatment options is weak. Adverse effects are frequent and sometimes serious, and many questions remain concerning long-term effects.
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy*; D017277:Drug Approval; D005060:Europe; D048788:Growth and Development / Q000187:drug effects; D006801:Humans; D008223:Lymphoma / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha